Literature DB >> 25457552

Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice.

Jose A Morales-Garcia1, Diana Aguilar-Morante1, Elena Hernandez-Encinas1, Sandra Alonso-Gil1, Carmen Gil2, Ana Martinez2, Angel Santos3, Ana Perez-Castillo4.   

Abstract

Different studies have suggested that the nucleotide cyclic adenosine 3', 5'-monophosphate can actively play an important role as a neuroprotective and anti-inflammatory agent after a brain injury. The phosphodiesterase 7 (PDE7) enzyme is one of the enzymes responsible for controlling specifically the intracellular levels of cyclic adenosine 3', 5'-monophosphate in the immune and central nervous systems. Therefore, this enzyme could play an important role in brain inflammation and neurodegeneration. In this regard, using different chemical inhibitors of PDE7 we have demonstrated their neuroprotective and anti-inflammatory activity in different models of neurodegenerative disorders, including Parkinson's disease (PD). In the present study, we have used the toxin 6-hydroxydopamine and lipopolysaccharide to model PD and explore the protective effects of PDE7B deficiency in dopaminergic neurons cell death. Lentivirus-mediated PDE7B deprivation conferred marked in vitro and in vivo neuroprotection against 6-hydroxydopamine and lipopolysaccharide toxicity in dopaminergic neurons and preserved motor function involving the dopamine system in mouse. Our results substantiate previous data and provide a validation of PDE7B enzyme as a valuable new target for therapeutic development in the treatment of PD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; New target; Oxidative stress; PDE7B; Parkinson disease; shRNA

Mesh:

Substances:

Year:  2014        PMID: 25457552     DOI: 10.1016/j.neurobiolaging.2014.10.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  10 in total

1.  Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats.

Authors:  Jose A Morales-Garcia; Sandra Alonso-Gil; Carmen Gil; Ana Martinez; Angel Santos; Ana Perez-Castillo
Journal:  Stem Cells Transl Med       Date:  2015-04-29       Impact factor: 6.940

Review 2.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

Review 3.  Aquaporin 4 in Traumatic Brain Injury: From Molecular Pathways to Therapeutic Target.

Authors:  Ehsan Dadgostar; Shiva Rahimi; Shahin Nikmanzar; Sina Nazemi; Mojtaba Naderi Taheri; Zahra Alibolandi; Michael Aschner; Hamed Mirzaei; Omid Reza Tamtaji
Journal:  Neurochem Res       Date:  2022-01-28       Impact factor: 3.996

Review 4.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

5.  Biological and Pharmacological Characterization of Benzothiazole-Based CK-1δ Inhibitors in Models of Parkinson's Disease.

Authors:  José A Morales-Garcia; Irene G Salado; Marina Sanz-San Cristobal; Carmen Gil; Ana Pérez-Castillo; Ana Martínez; Daniel I Pérez
Journal:  ACS Omega       Date:  2017-08-30

6.  CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson's disease.

Authors:  Jose A Morales-Garcia; Elena Gine; Elena Hernandez-Encinas; Diana Aguilar-Morante; Ana Sierra-Magro; Marina Sanz-SanCristobal; Sandra Alonso-Gil; Raul Sanchez-Lanzas; Jose G Castaño; Angel Santos; Ana Perez-Castillo
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

7.  Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.

Authors:  Matthias Höllerhage; Claudia Moebius; Johannes Melms; Wei-Hua Chiu; Joachim N Goebel; Tasnim Chakroun; Thomas Koeglsperger; Wolfgang H Oertel; Thomas W Rösler; Marc Bickle; Günter U Höglinger
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

8.  Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition.

Authors:  Fernando Bartolome; Macarena de la Cueva; Consuelo Pascual; Desiree Antequera; Tamara Fernandez; Carmen Gil; Ana Martinez; Eva Carro
Journal:  Alzheimers Res Ther       Date:  2018-02-20       Impact factor: 6.982

9.  The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.

Authors:  Ling Cao; Weilong Zhang; Xiaoni Liu; Ping Yang; Jing Wang; Kai Hu; Xiuru Zhang; Weiyou Liu; Xue He; Hongmei Jing; Xiaoliang Yuan
Journal:  Sci Rep       Date:  2019-11-18       Impact factor: 4.379

10.  Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles.

Authors:  Vanesa Nozal; Elisa Rojas-Prats; Inés Maestro; Carmen Gil; Daniel I Perez; Ana Martinez
Journal:  Int J Mol Sci       Date:  2021-03-22       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.